POLE and colorectal carcinoma: A recent study compared the treatment results of 26 patients with CRC with POLE/POLD1 proofreading-deficient mutations who received anti-PD-L1 and/or anti-CTLA-4 agents, with 516 patients from a cohort of patients with dMMR/MSI-H CRC who received the same treatment [8].